Why would the FDA approve another controversial drug to spur a woman’s libido with these data? And why no expert panel review?
AMAG Pharmaceuticals’ newly approved drug for spurring women’s sexual desire may never make much money, but it’s a big hit at sparking media attention.
The therapy — Vyleesi (bremelanotide) — got the green light from regulators on Friday evening, swiftly lighting up a range of stories around the world, from The New York Times to The Guardian. Several headlines inevitably referred to it as the “female Viagra,” invoking Pfizer’s old erectile dysfunction blockbuster.
But the two drugs have little in common.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 65,500+ biopharma pros reading Endpoints daily — and it's free.